October 27th 2023

By Ailsa Colquhoun

Time to improve the management of cardiorenal disease in primary care

DDA 2023 conference looks at optimising cardiorenal disease management

Using the dapagliflozin patient identification resource can help practices take a systematic, consistent and efficient approach to identify patients who may be considered for dapagliflozin, in-line with the current licensed indications.

That is a key message from the DDA 2023 conference presentation: Time to improve the management of cardiorenal disease in primary care by Mark Stone, practice pharmacist & partner at the Tamer Valley Practice, Launceston & Tamar Valley PCN, clinical director and DDA Board member.

At the conference, delegates were told that primary care plays a critical role in improving the lives of people living with cardiorenal disease.

• To identify individuals most at risk, the key questions to ask are:
• Which patients are at most risk of cardiorenal disease?
• Which patients could benefit most from dapagliflozin?

To support clinical review, practices were referred to the dapagliflozin patient identification resource.

View the presentation: Time to improve the management of cardiorenal disease in primary care